Will Australia follow the US and prohibit the patenting of genes and biological material?

A decision is expected later this year from the Australian High Court in D’Arcy v Myriad Genetics Inc. This case is essentially equivalent to the US Myriad Supreme Court case and thus will provide a definitive judgment in relation to the patentability of isolated genes in Australia, which the lower courts have unanimously found to

Update in the US Supreme Court landmark Myriad gene patent case

A decision is expected later this month from the US Supreme Court in the case of Association for Molecular Pathology v Myriad Genetics Inc, which is considering the patentability of isolated human genes claimed in patents held by Myriad Genetics Inc. Commentators present at the oral arguments, which were heard in April 2013, have indicated

Did a gene patent save Angelina Jolie’s life?

The recent news that Angelina Jolie tested positive for the BRCA1 mutation and has consequently undergone a prophylactic double mastectomy to guard against developing breast cancer has increased the intensity of the spotlight on the gene patent debate currently playing out in both the United States Supreme Court in Association for Molecular Pathology v Myriad Genetics

Gene patents are alive and well in Australia

In its long-awaited landmark decision, on 15 February 2013 our Federal Court confirmed that isolated genetic/biological material is patentable subject matter in Australia (Cancer Voices Australia v Myriad Genetics Inc. [2013] FCA 65 ). Gene patents have been the subject of two Senate Inquiries and Private Members’ Bills. In all instances, the arguments in support